SV

Street Verdict

Analyst Scorecard

PPLPHARMA · NSE

Piramal Pharma Limited

₹239.3

-0.15% (-₹0.35)

Prev. close

₹239.65

Volume

39,10,760

Delivery %

45.6%

As of

20 Nov 2026

Price history

₹239.3+₹28.77 (+13.67%) · 3M
18 Aug 2026 → 20 Nov 2026
20021022023024018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

Analysts lean bullish

1 analyst stance · last 90 days · one per analyst

Trackable

none in range

Long-Horizon

none in range

Commentary

1 · 1 bull / 0 neutral / 0 bear

Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded

Bullish 100% (1)Neutral 0% (0)Bearish 0% (0)
Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
Market commentary · 2 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About Piramal Pharma Limited

Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing; offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain management drugs, and other generic and speciality products; and analgesics, skin care, vitamin and mineral supplement, kids' wellness, digestives, and women's health, as well as geriatric care. In addition, the company operates as a contract development and manufacturing organization, providing process development, scale-up, and GMP manufacturing services for vaccines and biologics. The company was incorporated in 2020 and is based in Mumbai, India.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. Peter Daniel DeYoung

Headquarters

Mumbai

Employees

7,120

Key stats

Market cap

₹31,528.98 Cr

Dividend yield

0.00%

EPS (TTM)

₹-1.58

Beta (1Y · daily vs NIFTY 50)

1.04

Beta (5Y · monthly vs NIFTY 50)

1.44

Shares float

64.46 Cr

EPS · quarter ended Sept 2026

₹0.04

Upcoming earnings

27 Jan 2027

Financial Performance

01 · Financials

-5000 Cr0 Cr5000 Cr10000 Cr₹-4%-2%0%2%FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

-4-202₹FY23FY24FY25FY26

03 · Dividend Profile

0000₹0%0%0.1%0.1%12 Jul 2416 Jul 25
Dividend (₹/share)Annualised yield

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based · pre-FY23 not filed in verifiable form

-20%0%20%40%FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

Pre-FY23 not filed in verifiable form

0 Cr5000 Cr10000 Cr15000 Cr20000 Cr₹0×0.25×0.5×0.75×1×FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

Pre-FY23 not filed in verifiable form

0 Cr5000 Cr10000 Cr15000 Cr20000 Cr₹FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

Pre-FY23 not filed in verifiable form

-5000 Cr0 Cr5000 Cr10000 Cr₹FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY23FY24FY25FY26
₹7,081.55 Cr₹8,171.16 Cr₹9,151.18 Cr₹8,869.08 Cr
EBITDA
₹894.25 Cr₹1,366.81 Cr₹1,648.91 Cr₹993.53 Cr
₹-186.46 Cr₹17.82 Cr₹91.13 Cr₹-325.94 Cr
Diluted EPS
₹-1.54₹0.14₹0.68₹-2.46

Net income for Mar 2023 could not be checked against the company's own annual report: this page shows ₹-186.46 Cr while the annual report gives ₹69.50 Cr (137.3% apart).

EBITDA for Mar 2023 could not be checked against the company's own annual report: this page shows ₹894.25 Cr while the annual report gives ₹431.64 Cr (51.7% apart).

09 · Balance Sheet

Annual

Line itemFY23FY24FY25FY26
₹14,522.56 Cr₹15,311.81 Cr₹15,677.59 Cr₹17,965.04 Cr
₹5,637.08 Cr₹4,710.16 Cr₹4,856.47 Cr₹5,674.58 Cr
Stockholders' equity
₹6,773.50 Cr₹7,911.37 Cr₹8,125.47 Cr₹8,162.62 Cr

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY22FY23FY24FY25FY26
—₹483.89 Cr₹1,004.54 Cr₹892.30 Cr₹1,652.59 Cr
Investing cash flow
—₹-1,338.78 Cr₹-434.01 Cr₹-477.46 Cr₹-826.03 Cr
—₹817.79 Cr₹-422.36 Cr₹-440.83 Cr₹-38.97 Cr
Capital expenditure
—₹-964.75 Cr₹-712.04 Cr₹-664.38 Cr₹-890.02 Cr
End cash position
—₹53.23 Cr₹219.19 Cr₹182.32 Cr₹976.26 Cr

Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemOct 22Dec 22–Jun 23(3Q)Aug 23Sep 23–Dec 23(3Q)Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Promoter34.79%34.79%35.02%35.02%35.02%34.95%34.95%34.95%34.95%34.86%34.86%34.86%34.86%34.80%
Public64.81%64.82%64.59%64.60%64.61%64.58%64.61%64.65%64.71%64.57%64.63%64.70%64.81%64.72%
Employee trusts0.40%0.39%0.39%0.38%0.37%0.47%0.45%0.40%0.34%0.57%0.51%0.44%0.34%0.48%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Piramal Pharma Limited₹31,530.31 Cr₹239.92—3.86-4.0%0.70-3.3%+20.2%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

PPLPHARMA

Piramal Pharma Share Price Today Down 2.44%: What It Shows

Piramal Pharma shares fell to Rs 189.70, down 2.44% from the prior close of Rs 194.45, after opening near Rs 194.70 and reaching an intraday high of Rs 199.50. The decline occurs amid a large‑cap company reporting a P/B of 3.23x, negative ROE of 4.04% and EPS of Rs ‑2.36, figures that lag industry benchmarks.

2 days ago·Read at Univest
PPLPHARMA

Piramal Pharma acquisition: Company to buy remaining 26% stake in Yapan Bio

BusinessLine · 4 days ago